These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 9371375)
1. In vitro and in vivo antibacterial activities of CS-940, a new fluoroquinolone, against isolates from patients with respiratory infections. Miyazaki S; Domon H; Tateda K; Ohno A; Ishii Y; Matsumoto T; Furuya N; Yamaguchi K Antimicrob Agents Chemother; 1997 Nov; 41(11):2582-5. PubMed ID: 9371375 [TBL] [Abstract][Full Text] [Related]
2. Evaluation of OPC-17116 against important pathogens that cause respiratory tract infections. Wakebe H; Imada T; Yoneda H; Mukai F; Ohguro K; Ohmori K; Tamaoka H; Yabuuchi Y Antimicrob Agents Chemother; 1994 Oct; 38(10):2340-5. PubMed ID: 7840567 [TBL] [Abstract][Full Text] [Related]
3. Antibacterial activity of AM-1155 against penicillin-resistant Streptococcus pneumoniae. Tomizawa H; Tateda K; Miyazaki S; Yamaguchi K J Antimicrob Chemother; 1998 Jan; 41(1):103-6. PubMed ID: 9511043 [TBL] [Abstract][Full Text] [Related]
4. In vivo activity of HSR-903, a new fluoroquinolone, against respiratory pathogens. Yoshizumi S; Domon H; Miyazaki S; Yamaguchi K Antimicrob Agents Chemother; 1998 Apr; 42(4):785-8. PubMed ID: 9559783 [TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo antibacterial activities of a new quinolone, OPC-17116. Imada T; Miyazaki S; Nishida M; Yamaguchi K; Goto S Antimicrob Agents Chemother; 1992 Mar; 36(3):573-9. PubMed ID: 1320364 [TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo antibacterial activities of DC-159a, a new fluoroquinolone. Hoshino K; Inoue K; Murakami Y; Kurosaka Y; Namba K; Kashimoto Y; Uoyama S; Okumura R; Higuchi S; Otani T Antimicrob Agents Chemother; 2008 Jan; 52(1):65-76. PubMed ID: 17938194 [TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo antibacterial activities of CS-940, a new 6-fluoro-8-difluoromethoxy quinolone. Masuda N; Takahashi Y; Otsuki M; Ibuki E; Miyoshi H; Nishino T Antimicrob Agents Chemother; 1996 May; 40(5):1201-7. PubMed ID: 8723467 [TBL] [Abstract][Full Text] [Related]
8. Therapeutic effect of the quinolone prodrug prulifloxacin against experimental urinary tract infections in mice. Tomii Y; Ozaki M; Matsuda M; Honmura T; Nishimura I; Yamaguchi R; Adachi T; Okawa Y; Nishino T Arzneimittelforschung; 1996 Dec; 46(12):1169-73. PubMed ID: 9006794 [TBL] [Abstract][Full Text] [Related]
9. In vitro evaluation of sparfloxacin activity and spectrum against 24,940 pathogens isolated in the United States and Canada, the final analysis. Jones RN; Ballow CH; Schentag JJ; Johnson DM; Deinhart JA Diagn Microbiol Infect Dis; 1998 May; 31(1):313-25. PubMed ID: 9597392 [TBL] [Abstract][Full Text] [Related]
10. The activity of grepafloxacin against respiratory pathogens in the UK. Wise R; Andrews JM J Antimicrob Chemother; 1997 Dec; 40 Suppl A():27-30. PubMed ID: 9484870 [TBL] [Abstract][Full Text] [Related]
11. In vitro activity of BAY 12-8039, a novel 8-methoxyquinolone, compared to activities of six fluoroquinolones against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. Brueggemann AB; Kugler KC; Doern GV Antimicrob Agents Chemother; 1997 Jul; 41(7):1594-7. PubMed ID: 9210692 [TBL] [Abstract][Full Text] [Related]
12. Comparison of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of Neisseria gonorrhoeae harboring quinolone resistance alterations in GyrA and ParC. Deguchi T; Yasuda M; Nakano M; Ozeki S; Kanematsu E; Fukuda H; Maeda S; Saito I; Kawada Y Chemotherapy; 1997; 43(4):239-44. PubMed ID: 9209780 [TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo antimicrobial activities of T-3811ME, a novel des-F(6)-quinolone. Takahata M; Mitsuyama J; Yamashiro Y; Yonezawa M; Araki H; Todo Y; Minami S; Watanabe Y; Narita H Antimicrob Agents Chemother; 1999 May; 43(5):1077-84. PubMed ID: 10223917 [TBL] [Abstract][Full Text] [Related]
14. Comparative in vitro assessment of sparfloxacin activity and spectrum using results from over 14,000 pathogens isolated at 190 medical centers in the USA. SPAR Study Group. Ballow CH; Jones RN; Johnson DM; Deinhart JA; Schentag JJ Diagn Microbiol Infect Dis; 1997 Nov; 29(3):173-86. PubMed ID: 9401810 [TBL] [Abstract][Full Text] [Related]
15. In vitro activity of HSR-903, a new quinolone. Takahashi Y; Masuda N; Otsuki M; Miki M; Nishino T Antimicrob Agents Chemother; 1997 Jun; 41(6):1326-30. PubMed ID: 9174193 [TBL] [Abstract][Full Text] [Related]
16. Antibacterial activity of tosufloxacin against major organisms detected from patients with respiratory or otorhinological infections: comparison with the results obtained from organisms isolated about 10 years ago. Hasegawa M; Sato Y; Kanayama A; Matsuzaki K; Muraoka H; Amano A; Saika T; Kobayashi I J Infect Chemother; 2006 Jun; 12(3):152-6. PubMed ID: 16826349 [TBL] [Abstract][Full Text] [Related]
17. In vitro activity of HSR-903, a new oral quinolone, against bacteria causing respiratory infections. Watanabe A; Tokue Y; Takahashi H; Kikuchi T; Kobayashi T; Gomi K; Fujimura S; Nukiwa T Antimicrob Agents Chemother; 1999 Jul; 43(7):1767-8. PubMed ID: 10390240 [TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo antibacterial activities of Q-35, a novel fluoroquinolone. Iwasaki H; Miyazaki S; Tsuji A; Yamaguchi K; Goto S Chemotherapy; 1995; 41(2):100-12. PubMed ID: 7758353 [TBL] [Abstract][Full Text] [Related]
19. In-vitro activity of four new fluoroquinolones. García-Rodríguez JA; García Sánchez JE; García García MI; Fresnadillo MJ; Trujillano I; García Sánchez E J Antimicrob Chemother; 1994 Jul; 34(1):53-64. PubMed ID: 7961215 [TBL] [Abstract][Full Text] [Related]
20. Sparfloxacin, a new generation fluoroquinolone against S. pneumoniae respiratory infections. Niki Y; Tamada S; Nakabayashi M; Soejima R Drugs; 1995; 49 Suppl 2():420-2. PubMed ID: 8549385 [No Abstract] [Full Text] [Related] [Next] [New Search]